Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting.

Both posters will be made available on the Zynerba corporate website.

The first poster titled, "Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]" describes responder thresholds representing individual patient-level changes that the company believes are indicative of meaningful treatment benefit for the ABC-CFXS social avoidance, irritability, and socially unresponsive/lethargic subscales. The poster was presented today (April 29).

READ: Zynerba Pharmaceuticals says it is fully funded into 2024; lays out plans to advance four Zygel indications in 4Q results

Zynerba said the authors concluded:

- Responder thresholds for meaningful within-patient behavioral change on key domains of the ABC-CFXS were determined using anchor-based methods based upon US Food and Drug Administration guidance for caregiver-reported outcomes.
- The responder thresholds for meaningful within-patient behavioral change in CONNECT-FX corresponded to the following reductions: 3 or more points on the ABC-CFXS Social Avoidance subscale; 9 or more points on the ABC-CFXS Irritability subscale; and 5 or more points on the ABC-CFXS Socially Unresponsive/Lethargic subscale.
- These thresholds serve as a basis for evaluating clinically meaningful treatment effects at the individual patient level in clinical trials of children and adolescents with FXS as demonstrated for Zygel (ZYN2) in CONNECT-FX.
- Zygel provided meaningful improvements in behavioral symptoms of FXS in patients with >90% methylation of the FMR1 gene.

"We believe these data demonstrate the ABC-CFXS subscales capture behaviors that are impactful and meaningful in clinical trials of children with FXS," said Dr Joseph M. Palumbo, chief medical officer of Zynerba, in a statement. "Therefore, we remain confident that these subscales are fit for purpose for measuring clinical trial endpoints in FXS."

The second poster titled, "A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]" will be presented on April 30 and focuses on the findings in the CONNECT-FX study for the 80% of randomized patients whose FMR1 genes were highly methylated.
This poster will be presented in Poster Session II beginning at 1 pm ET.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickM Graham
Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists, and professional investors, Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers, and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter. You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual cash compensation of typically up to $25,000.